MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

ImmunityBio Inc

Fermé

SecteurSoins de santé

3.05 4.1

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.89

Max

3.12

Chiffres clés

By Trading Economics

Revenu

27M

-59M

Ventes

1.4M

7.6M

BPA

-0.08

Marge bénéficiaire

-783.62

Employés

680

EBITDA

946K

-40M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+99.34% upside

Dividendes

By Dow Jones

Prochains Résultats

7 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

273M

2.7B

Ouverture précédente

-1.05

Clôture précédente

3.05

Sentiment de l'Actualité

By Acuity

21%

79%

47 / 386 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bullish Evidence

ImmunityBio Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

29 janv. 2025, 15:59 UTC

Principaux Mouvements du Marché

ImmunityBio Shares Rise After Collaboration, Supply Agreement With BeiGene

23 avr. 2024, 10:51 UTC

Principaux Mouvements du Marché

ImmunityBio Shares Soar Premarket on FDA Nod for Anktiva

24 oct. 2024, 13:50 UTC

Acquisitions, Fusions, Rachats

This Biotech Stock Could Rocket 800%, Analyst Says -- Barrons.com

Comparaison

Variation de prix

ImmunityBio Inc prévision

Objectif de Prix

By TipRanks

99.34% hausse

Prévisions sur 12 Mois

Moyen 6.08 USD  99.34%

Haut 8 USD

Bas 4.25 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

3 ratings

2

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

2.92 / 3.26Support & Résistance

Court Terme

Very Strong Bullish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

47 / 386Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Moyen

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos ImmunityBio Inc

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.